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Abstract 
Intraoperative fluorescence imaging is particularly well-suited for surgical applications due to its 
inherently high sensitivity, resolution, and ability to provide images in real-time. To date, the 
intraoperative observation of fluorescence has largely been subjective. With the need to show 
objective evidence in order to demonstrate the benefit of this technique, quantitative data needs to 
be provided to overseeing regulatory bodies. Standardization of fluorescence imaging protocols 
would improve reproducibility and minimize inter- and intra-institution variance. This would allow 
studies to be conducted using the same injection techniques, imaging times, reconstruction 
methods, and analyses. Here, we provide recommendations for standardized methodologies with 
the goal of setting a minimum requirement for reporting fluorescence-guided surgery results based 
on both qualitative and (semi-) quantitative data collection. Clinical trials using fluorescence-guided 
surgery should present results of three critical elements; 1) intra-operative imaging, 2) specimen 
mapping and pathology correlation, and 3) target validation. Qualitative analyses should consist of a 
bright field image, black-and-white fluorescence image, pseudo-colored fluorescence overlay image, 
and/or heat-map whereby fluorescence signal intensity differences are displayed on a color 
spectrum. Quantitative analyses should include 1) intraoperative data (consisting of images or video, 
raw numeric values and ratios); 2) specimen mapping, for correlation of fluorescence with the 
presence of disease (performed using fresh tissue); and 3) target validation (designed to determine 
fluorescence intensity relative to receptor density of a specific area). Including the aforementioned 
methods of both qualitative and quantitative analyses will ensure that trial results are comparable 
and could be collated in future studies to expedite FDA approval. 
Key words: Optical imaging, fluorescence, clinical trial, standardization, result reporting 
Introduction 
An incremental improvement in oncologic 
surgical outcomes can be obtained by successful 
identification of visually occult disease and 
tumor-positive margins during surgery, which will 
have a significant impact on overall cancer survival. 
Interest in cancer-specific intraoperative molecular 
imaging has undergone rapid growth. This 
substantial interest is not surprising considering the 
robust potential of the technique to achieve 
subclinical tumor-detection and improved surgical 
guidance. Fluorescence-guided surgery (FGS) is 
particularly well-suited for surgical applications due 
to its inherently high sensitivity, resolution, and 
ability to provide images in real-time [1]. In recent 
years, the number of early phase clinical trials using 
FGS has drastically risen, and shifted towards the use 
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of dyes emitting in the near-infrared rather than in the 
visible part of the light spectrum. An example of a 
commonly used near-infrared fluorescent (NIRF) dye 
is indocyanine green (ICG). ICG achieves its 
tumor-targeting through “second window imaging,” 
which is based on the enhanced permeability and 
retention (EPR) effect [2, 3]. While safe, ICG is a 
non-specific agent that is rapidly cleared by the liver 
and excreted in bile. Currently, most strategies use a 
NIRF dye that is conjugated to a targeting vehicle 
directed against a tissue of interest, such as a 
tumor-specific agent, and this combination permits 
optimal cancer-specific detection [4, 5]. However, 
human testing using such novel NIRF-guided surgical 
agents has thus far only been conducted in early 
phase trials to establish safety and efficacy [6-13]. 
These trials are unable to show benefit over the 
current standard-of-care; larger phase II/III trials are 
needed to demonstrate superiority prior to obtaining 
regulatory approval and wide-spread adoption into 
practice. Early stage clinical trials are crucial to 
providing data to support in vivo application, surgical 
specimen mapping, and target validation. These three 
elements should be evaluated using a standardized 
methodology that can be used to advance these 
technologies through regulatory pathways into 
routine clinical use.  
Positron emission tomography (PET) imaging 
represents a clear precedent for the introduction of 
standardization into FGS. Since its establishment in 
1984, numerous articles have been published 
describing the need for standardization of the 
technology with regards to clinical application [14-16]. 
These studies showed that strict standardization of all 
aspects of imaging and data analysis is required to 
obtain quantitative, accurate, reliable, precise and 
reproducible results. Similarly, multiple studies have 
been performed investigating the concordance of PET 
results obtained at different institutions [15, 17, 18]. 
Developing a standardized approach will minimize 
variability between studies in addition to facilitating 
the development of multicenter studies, thus allowing 
for direct comparison of results within and between 
clinical trials. Moreover, it can potentially allow for 
future direct translation of results to other centers. 
Although often difficult to test in clinical trials, 
the qualitative representation of fluorescence imaging 
data is critical, as surgeons make intraoperative 
decisions based on their own interpretation of images 
generated and displayed by the imaging device. To be 
valuable, high-resolution images need to be generated 
in real-time, without delayed image processing. In 
many cases, the value and objectivity of qualitative 
data is questioned, though in the case of FGS its 
representation is of the utmost importance to the 
technology’s implementation and utility.  
Simultaneously, quantitative data plays a key 
role in the analysis of FGS clinical trials. Currently, 
quantitative data is difficult to generate as compared 
to qualitative data, and since FGS is primarily a visual 
tool for the surgeon, the use of quantitative data has 
been less emphasized in the first early phase clinical 
trials. However, with the need to show objective 
evidence to demonstrate the superiority of FGS 
techniques, quantitative data should also be provided 
to the regulatory bodies.  
Here, we propose a methodology for reporting 
results from fluorescence-guided oncologic surgery 
studies (Figure 1). Our proposed method is based on 
the minimum requirements for the presented data 
from all phases of a clinical trial, including 
intraoperative imaging, ex vivo imaging, and 
pathologic correlation, which should be represented 
using both qualitative and quantitative data. 
Quantitative data 
In vivo fluorescence quantification is challenging, 
since the measured fluorescence depends not only on 
the concentration of the imaging agent, but on 
multiple parameters, such as intrinsic 
autofluorescence of tissue, the sensitivity of the 
imaging device, the absorption and scattering 
properties of the tissue, and photobleaching. All these 
parameters can influence the accuracy of 
quantification [19-21]. Standardization of 
quantification in fluorescence imaging protocols 
would improve reproducibility and minimize inter- 
and intra-institution variance, and studies should be 
conducted using the same injection technique, 
imaging time, reconstruction method, and analysis 
[14]. Such strategies are critical for reproducibility in 
multi-institutional clinical trials but are not easy to 
achieve. Use of phantoms will be beneficial to 
determine how well individual cameras and centers 
perform in the technical aspects of image acquisition, 
data processing, and analysis [22]. In multicenter 
studies using PET imaging, the submission of a 
phantom scan is usually required periodically for 
scanner calibration and reproducibility [23]. 
Perhaps the largest research effort to quantify 
fluorescence in vivo has been focused on the 
measurement of photosensitizer concentration prior 
to and during photodynamic therapy (PDT) [20, 21, 
24, 25]. Because the effect of PDT depends directly on 
the concentration of sensitizer used, there is a high 
need for measuring this quantity quickly and 
noninvasively [20]. Kim et al. described a noninvasive 
in vivo method to determine fluorophore 
concentration in neurosurgery using 5-ALA [19]. 
Using a fiber-optic probe, the fluorophore 
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concentration is calculated from the quantitative 
fluorescence spectrum, which is the fluorescence 
emission spectrum corrected for optical attenuation of 
the tissue, thus quantifying the observed fluorescence 
[19]. These handheld fiber-optic probes need to 
simultaneously collect tissue fluorescence and diffuse 
reflectance spectra in vivo [26]. The method is 
performed using specific fiber-optic probes that touch 
the tissue, which requires a separate device in 
combination with the fluorescence camera for 
intra-operative navigation. Another complicating 
factor of this method is the need to identify the optical 
properties of tissues and the variation of these 
properties, which are mostly unknown [26].  
Achieving absolute in vivo quantification is 
unlikely, since the current fluorescence imaging 
systems are not equipped to generate quantified 
imaging data, but a semi-quantification of the 
fluorescence signal should be possible. Similar to PET 
imaging, where maximum standard uptake values 
(SUVmax) are calculated based on the administered 
radioisotope dose and the patient weight, one can also 
calculate fluorescence signal uptake values by 
correcting for tissue surface area [27]. In fluorescence 
imaging, only fluorescence arising from <1 cm depth 
will contribute to the measured signal. Therefore, 
signal should be corrected for surface area since 
corrections either for weight or volume will not 
necessarily generate a representative value. 
Consequently, it is recommended for fluorescence 
imaging to provide standardized reports on surface 
area-adjusted values where feasibly measured by ex 
vivo imaging. For example, adjusted from the formula 
for SUV values, mean fluorescence intensity (MFI) 
could be calculated as MFIcorrected = fluorescence 
intensity of tissue of interest / (injected dose/surface 
area of the tissue) [28].  
As described above, quantification of 
fluorescence signal is still in its infancy. Ultimately, it 
is expected that this objective measure is going to play 
a major role in providing evidence of patient benefit. 
Next to the extensive investments in novel agents and 
clinical cameras, innovative solutions are being 
developed for the quantification of fluorescence 
imaging signals in the ex vivo setting. Several groups 
are working on the real-time detection of the actual 
amount and concentration of the fluorescent agent 
that accumulates in tissues. By scanning part of the 
tissue or by taking point measurements, the 
concentration can be determined, leading to exact 
quantification [19, 29]. Another method to objectify 
and automate quantification is by machine learning. 
Here, the software can be trained to identify the 
fluorescence cut-off value for true-positive 
fluorescence and true-negative fluorescence. With a 
learning set, these values can be validated and 
applied to all patients injected with the same agent 
and dose [30]. For now, these methods are not 
commercially available, and further research is 
required to validate their applicability, but 
semi-quantification of the fluorescence signal is 
already possible without these novel devices using 
methods described below. 
Quality control procedures 
FGS is intrinsically linked to the sensitivity of the 
 
Figure 1. Standardized assessment of reporting results in fluorescence-guided oncologic surgical trials for all aspects of the clinical trial: intraoperative imaging, ex 
vivo imaging and pathologic assessment. During the intraoperative assessment, focus should remain on imaging at predetermined timepoints intraoperatively. Ex vivo 
imaging will ensure exact tumor mapping to correlate imaging results to pathology. During pathologic assessment the focus should be on confirmation of fluorophore 
targeting to tumor tissue [adapted with permission from [48], copyright 2018]. 
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imaging device used. Currently, various imaging 
systems, ranging from large open-field cameras to 
minimally-invasive endoscopic cameras, are available 
for NIRF excitation and emission signal detection 
during surgery and ex vivo. Consequently, results 
from different imaging systems are hard to compare. 
This is one of the main reasons that the FDA primarily 
reviews combination products, instead of an imaging 
agent and device separately [31]. This is in contrast to 
PET agents and scanners, where the implementation 
of quality control (QC) procedures have led to an 
established method to verify consistency, linearity, 
and safety functions of PET scanners. For PET 
imaging, the National Electrical Manufacturers 
Association (NEMA) has formulated performance 
standards, to which manufacturers need to adhere 
[32]. For fluorescence imaging devices, this is still far 
from standard practice, with only safety standards 
currently available. Incorporating documentation on 
performance testing can help to identify relevant 
characteristics (e.g., spatial resolution, uniformity, 
sensitivity, dynamic range), provide guidelines for 
testing (e.g., phantom material property 
range/geometry, methods for calculating metrics), 
and describe viable test methods for the validity of 
performance characteristics [31].  
General aspects of fluorescence data 
analysis 
Ideally, all acquired FGS data should be 
analyzed for the correlation between imaging results 
and pathology using a quantitative and qualitative 
approach. 
Detection threshold 
Targeted agents are usually present in the tissue 
of interest at nanomolar concentrations, which 
requires sensitive cameras with low detection 
thresholds. Analysis of this threshold for different 
imaging systems and agents is important when 
evaluating agents for their intended use. If one aims to 
detect micrometastases, the sensitivity of the camera 
and the specificity of the agent should both be 
extremely high. DSouza et al. performed a study to 
determine the detection limit of various fluorescent 
imaging systems using dye concentrations in a 
phantom and showed that devices with higher bit 
depths, variable electronic gain settings, and 
background-light correction during acquisition, had 
the highest sensitivities [33]. Previously, we have 
shown that small numbers of cancer cells can be 
detected in optimized ex vivo settings both 
preclinically (2.4×104 cells) and clinically (< 5 mm) 
[34]. 
Quantification parameters 
Significant variations can occur when reporting 
on fluorescence signal intensities since the value 
remains dependent on the way the images are 
analyzed. Below we discuss various methods to 
quantify fluorescence imaging data.  
Mean fluorescence intensity 
The mean fluorescence intensity (MFI) is a 
measurement of the fluorescence signal in a region of 
interest (ROI) divided by the area within that ROI 
(either in pixels or cm2). The MFI is typically shown in 
arbitrary units of fluorescence (AU) or total number of 
photons detected by the device for each pixel, or per 
cm2. Arbitrary values are generally used for relative, 
ratiometric quantification to determine the fold 
difference or change between various samples that are 
analyzed in parallel. Devices that use a scaled 
algorithm for determining fluorescence signal also use 
AU.  
The MFI can also be shown in relative 
fluorescence units (RFU), which is a relative unit of 
measurement compared to a reference measurement 
using the same ROI area. In PET imaging a defined 
background is determined to compare to the SUVmax 
value in order to determine the presence of increased 
uptake. As with PET imaging, it may be 
recommended to use the maximum fluorescence 
value, since this is independent from an ROI, less 
observer-dependent and more reproducible 
compared to the mean value. The primary 
disadvantage is that a maximum value is more 
susceptible to noise. Comparing the maximum 
fluorescence value to that of a set background (Table 
1), may be used to correct for this noise. 
Tumor-to-background ratio 
When addressing the quality of an imaging 
agent to provide tumor-specific contrast, it has 
generally been related to a ratio such as 
tumor-to-background ratio (TBR), signal-to-noise 
ratio (SNR) or contrast-to-noise ratio (CNR). In the 
past, studies aimed for a TBR of >2.5, since it was 
thought that any lower rate was insufficient to 
identify cancerous tissue intraoperatively [2, 35]. 
However, an intraoperative TBR of >2.5 is relatively 
hard to achieve in a clinical setting with currently 
available agents and imaging systems, although at 
this TBR the tumor can be clearly distinguished from 
the surrounding tissue. While a higher signal in the 
tumor when compared to surrounding tissue is 
preferred, there are many other variables that 
contribute to an agent’s ability to differentiate normal 
from diseased tissues. Therefore, it may not be 
appropriate to identify a specific number as a 
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minimum value before one can determine there is 
“sufficient contrast”. At a minimum, the difference in 
signal needs to be high enough for the surgeon to 
differentiate tumor from normal tissue—in our 
experience a TBR >3.0 in preclinical studies and >1.5 
in clinical studies would be appropriate for further 
studies. 
Another important note is that TBR is highly 
dependent on the dynamic range of the imaging 
devices used in addition to the variability in 
properties of the chosen background tissue. The 
background will greatly influence the TBR value, and 
currently no guidelines exist regarding an appropriate 
background for various cancer types. If unrealistically 
high values of TBR are set as a standard, it is likely 
that only surrounding tissues with virtually no 
fluorescence will be candidates for employing these 
techniques. However, to ensure clinical applicability 
of the technique, the background tissue is inherently 
in close proximity of the tumor even when this tissue 
displays some intensity of fluorescence. For example, 
in pancreatic cancer surgery, muscle would not be an 
appropriate background, whereas for head and neck 
cancer, muscle would be appropriate based on the 
surgical field of view (Table 1). 
Signal-to-noise ratio (SNR) 
The SNR is the quotient of the MFI measured in a 
ROI and the standard deviation (SD) of the signal 
intensity in a region outside the boundaries of the 
object being imaged (i.e., a region from which the 
tissue’s fluorescence signal is zero) [36]. There are two 
forms of noise in images: random and structured. 
Random noise (or statistical noise) is directly related 
to the number of signals coming from the imaging 
agent. Structured noise refers to non-random 
variations in counting rates. The latter will adversely 
affect the interpretation and analysis of the images. 
Examples of structured noise are organ motion, and 
imaging instrument non-uniformities [37].  
Contrast-to-noise ratio (CNR) 
To ensure only contrast through targeted uptake 
is measured, and contrast through non-specific EPR is 
excluded, contrast can be quantified by calculating the 
average signal in the tumor and subtracting the 
average signal in the selected background tissue. This 
value can be divided by the standard deviation of the 
background to estimate the CNR [38]. This technique 
may be particularly helpful to assess off-target 
accumulation in non-cancerous tissues that express 
the biomarker of interest. CNR is especially useful in 
situations where the background and tumor signals 
fluctuate widely. In these cases, the TBR value could 
be the same as compared to a situation with a more 
constant signal profile. However, the tumor would be 
more consistently clearly visible in case of a constant 
pattern. In situations with more fluctuation, CNR 
would show a difference in value, providing a more 
representative value that assists in distinguishing true 
contrast from noise [38].  
When detecting lesions in the body, a high SNR 
alone will not guarantee that sufficient contrast exists 
to make the lesion detectable. Therefore, SNR should 
be used to assess one single image. CNR on the other 
hand can be used to identify fluctuations within one 
patient over time as it compares a measure of signal 
fluctuations to noise. In summary, SNR is a good 
measure to assess data quality of a single image, and 
CNR provides knowledge regarding how easy or 
hard it is to detect signal fluctuations over time [36]. 
Sensitivity and specificity 
A topic of constant debate in the field of FGS is 
the reporting of test characteristics. Certain groups 
choose not to report sensitivities and specificities in 
early phase clinical trials, since the number of patients 
is insufficient for a powered calculation. Some groups 
use multiple separate specimens from each patient to 
generate a sufficient sample size for determining test 
characteristics. We believe that reporting on 
sensitivity and specificity in early trials is important in 
order to determine the potential of the fluorescence 
imaging agent for FGS. In larger clinical trials in later 
phases, the additional benefit of sensitivity and 
specificity should focus on improving or 
complementing the surgeon’s assessment. 
 
Table 1. Suggestions for tissue to appoint as background for quantitative fluorescence imaging analysis. 
Cancer type and location Ideal background Appropriate background 
Breast Uninvolved breast tissue Adipose tissue 
Head and neck Muscle Skin or mucosa 
Colorectal Uninvolved bowel serosa Normal bowel mucosa 
Pancreas Peritumoral inflammation Normal pancreatic tissue 
Lung Uninvolved lung tissue Skin 
Brain Uninvolved brain tissue Uninvolved brain tissue 
Hepatocellular and CRLM Immature hepatocytes Uninvolved liver tissue 
Prostate Uninvolved prostate tissue Connective tissue 
Parathyroid Thyroid tissue Muscle 
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Demonstration of value in early phase 
clinical trials: Three critical elements 
1. Intraoperative data collection 
Real-time fluorescence tumor imaging should 
demonstrate sufficiently higher contrast enhancement 
in the tumor relative to surrounding normal 
structures in order to augment the current standard of 
care. During minimally-invasive and robotic surgery, 
this real-time detection of fluorescence is easily 
integrated as the current technology requires the 
surgeon to operate using a screen to visualize the 
surgical field. However, to properly interpret a 
positive fluorescence signal that will subsequently 
affect clinical decision-making, consensus should be 
reached regarding validation of fluorescent markers 
and imaging devices designed to differentiate tumor 
from peri-tumoral tissue. To date, an insufficient 
number of standardized studies have been performed 
to reach this type of consensus.  
Developers of strategies for intraoperative 
imaging should recognize that the surgical approach 
varies significantly by tumor type, and that each 
approach has a unique workflow. The incorporation 
of intraoperative FGS into the surgical workflow will 
be individualized to the type of procedure being 
performed, and the type of cancer being resected. For 
example, in the case of ovarian cancer, brain cancer or 
peritoneal metastases during a cytoreduction and 
hyperthermic intraperitoneal chemotherapy 
procedure (HIPEC), the primary goal is a more 
complete debulking [39]. In these cancer types, it is 
known that extensive debulking leads to prolonged 
survival for patients [40]. Here, FGS has the potential 
to be beneficial in identification of subclinical disease, 
or occult tumor deposits [12]. For other tumor types, 
complete resection is the key to prolonged survival. In 
these situations, FGS will play a crucial role in 
assessing the resection bed for residual tumor after 
initial resection or to assess the margins of the 
specimen [6, 9, 13, 41]. Next steps in treatment could 
be informed by the presence of residual fluorescence, 
warranting either further resection or, for example, 
novel techniques such as applying PDT to the 
resection bed [42]. 
Intraoperatively, FGS is particularly important 
for: 1) Identification of tumor; 2) Assessment of 
resection margins, both before the resection for 
operative planning and after to assess the wound bed; 
and 3) Detection of tumor-positive lymph nodes, 
especially in locations that would suggest metastatic 
disease. In this case, for example, FGS could inform 
clinical decision making by aborting a surgery when 
there is no oncologic benefit. 
Margin assessment in the OR 
One of the biggest gaps in oncologic surgery 
remains the high rate of positive margins following 
surgical resections, which directly correlates with 
poor survival and locoregional recurrence [43-45]. 
Both the in vivo assessment of the resection bed and 
the ex vivo assessment of the specimen are critical to 
ensure negative margins. The current approach to 
margin assessment in most tumor types is 
circumferential analysis of the resected specimen 
using frozen sections [46]. Therefore, only a fraction of 
the tumor mass can be analyzed due to the limited 
sampling that is feasible with frozen sectioning. A 
tumor-specific fluorescent contrast agent can be 
leveraged to perform fluorescence mapping of the 
surgical specimen. Fluorescent ‘hot spots’ could be 
used to direct clinicians toward suspicious regions, 
and thereby reduce sampling error. The detection of a 
fluorescence signal using back-table benchtop devices 
could also result in reduction of time needed for 
specimen analysis, since sampling can be performed 
based on fluorescence-positive areas, as opposed to 
sampling all surfaces of a large tumor specimen (i.e., 
hepatic tumor resections). 
Data representation from intraoperative imaging 
During surgery, fluorescence imaging should be 
performed at multiple fixed time points as outlined in 
the clinical trial protocol and standard operation 
procedure (SOP). For example, one can identify three 
imaging time points to be used in most trials: First, 
while scanning the area of interest for the localization 
of the primary tumor and/or detection of metastases 
prior to excision. Second, once the tumor has been 
exposed while still in situ, with surrounding normal 
tissue in the field of view. And third, after resection of 
the primary tumor for assessment of the wound bed. 
During surgery, both endoscopic and open-field 
imaging systems can be used. In some operative cases, 
such as an abdominal laparoscopy that is converted to 
an open procedure, both systems can be used at 
different timepoints. Since the two devices will 
generate data that is not necessarily comparable, it is 
important to clearly state which device’s data will be 
used in a clinical trial and document this in the SOP. 
Depending on the capabilities of the fluorescence 
camera, multiple images should be obtained in each 
setting; a bright field image, a black-and-white 
fluorescence image, a pseudo-colored fluorescence 
overlay image, and/or a heat-map whereby 
fluorescence signal intensity differences are displayed 
in different colors (Figure 2). Ex vivo imaging of fresh 
tissue should be presented in a similar manner. 
Quantitative data of intraoperative images should 
consist of a numeric value representing fluorescence 
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signal. This can either be reported in MFI values or in 
a ratio such as TBR.  
The development process of an optimal 
intraoperative imaging strategy should keep in mind 
the specific nature of the surgical workflow in order to 
minimize interruptions and facilitate the adoption of 
this technology. Early phase clinical trials are 
designed to demonstrate the safety, appropriate dose 
and tumor specificity of experimental agents. For 
these trials, the secondary outcomes primarily focus 
on the tumor-specific contrast that is generated 
between tumor tissue and background tissue using 
the agent-device combination. Regulatory standards 
ensure the workflow of these early phase trials 
maintain the standard of care, which makes it difficult 
to objectively assess the potential clinical value and 
patient benefit of FGS. For larger clinical trials, 
clinically relevant endpoints that necessitate 
experimental assessment will be needed to 
demonstrate superiority to the current standard of 
care. Examples of secondary endpoints include 
improved detection of tumor-positive margins, 
decreased morbidity, reduced local recurrence, or 
increased efficiency in the operating room [31]. These 
endpoints can be directly correlated with known 
statistics pertaining to survival, thereby 
demonstrating clinical benefit. 
It is important to recognize that the success of 
these trials will be influenced by the parameters of the 
clinical imaging devices employed. Not all imaging 
devices are able to show a TBR in real-time, and the 
significant differences in sensitivity among the 
various devices will make it challenging to achieve 
consistency and compare results regarding the clinical 
utility of tumor-specific contrast agents. Another 
limitation that should be recognized is the inability to 
directly correlate intraoperative images with 
pathology results in real-time. Therefore, dependence 
on ex vivo imaging to confirm tumor status will 
remain a critical component of FGS validation, 
especially in early phase clinical trials where 
confirmation of tumor specificity is critical. To 
circumvent this limitation, ex vivo imaging can be 
done in the form of back-table fluorescence imaging in 
the operating room using either a clinical camera or a 
bench-top device developed for this purpose. These 
results can later be directly correlated to the 
pathological assessment [6-9, 12, 13, 27, 41]. 
2. Specimen mapping 
An important stage in the validation of FGS is 
the correlation of the fluorescence imaging-based 
results with the pathologic findings, which is used to 
determine if the fluorescence signal is specifically 
localized to the tumor. It is recommended that the 
correlation be performed in a standardized and 
rigorous method as described in Figure 3. After 
analysis of the resected fresh tissue, the surgical 
specimen is processed into bread loaves (either before 
or after formalin-fixation) and later into blocks to be 
placed in cassettes (Figure 3). These cassettes are then 
imaged on a fluorescence scanner both before and 
after paraffin embedding. Finally, these cassettes are 
processed into microscopy slides where fluorescence 
can then be correlated with hematoxylin and eosin 
(H&E) histopathology. These steps are possible when 
the fluorescent capabilities of the probe are 
maintained after formalin fixation. Additional 
immunohistochemical correlation of the target of 
interest and H&E should be performed to determine 
co-localization of the target and fluorescence, which 
will be discussed later. 
 
 
 
Figure 2. Suggested method of reporting intra-operative imaging results. This includes a bright field image (A), black-and-white fluorescence image (B), fluorescence 
overlay image (C), and fluorescence heat-map (D). In this case, an example of a tumor-positive lymph node during abdominal surgery is shown. 
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Figure 3. Detailed overview using a clinical example of the ex vivo mapping process of a surgical specimen to ensure exact correlation of the surgical specimen with 
pathologic assessment. During step 1, the fresh tissue specimen is imaged ex vivo to ensure images from all angles. After formalin fixation, the specimen is mapped and 
sliced into bread loaves in step 2. Fluorescence imaging is subsequently performed of the bread loaves separately. In step 4, cassettes are made that include one bread 
loaf each and are imaged either on a fluorescence scanner or in a closed-field imaging system. The cassettes are then paraffin-embedded and sectioned to produce 
microscopy slides. In step 5, these slides are used for pathologic assessment and fluorescence scanning. 
 
Mapping process of the gross surgical specimen 
To facilitate the processing of the specimen, a 
bright-field image of the gross surgical specimen can 
be acquired and used as a reference map as the 
specimen is sectioned and placed into cassettes. The 
origin of the cassette-specific sections can be drawn on 
a printed or digital image of the primary specimen 
and saved for later correlation at the time of 
histopathologic study. This methodology is 
commonly employed during pathological processing 
of large surgical specimens. Precise imaging of the 
gross specimen and close correlation with 
histopathologic sections increases the efficiency and 
accuracy of pathologic assessment and enables 
consistent and accurate interpretation of the 
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technique’s specificity. This method is anecdotally 
used during Mohs surgery and is also described in the 
standardized pathologic assessment of breast cancer 
specimens [47]. It is important to maintain the 
specimen orientation relative to the patient so that the 
slide-mounted section can be registered back to the 
primary specimen, and ultimately to the wound bed. 
This approach will allow the clinician to determine if 
fluorescence observed on either the resected specimen 
or in the wound bed is clinically relevant and a source 
of potential recurrence. 
Data representation of ex vivo imaging 
After removal from the patient, the fresh 
specimen is imaged at the back-table using a benchtop 
device or the surgical camera. Fresh tissue should be 
imaged when possible and fluorescence intensity 
should be expressed relative to the surface area of the 
specimen.  
After imaging the fresh surgical specimen, the 
tissue should be formalin-fixed prior to being 
processed into bread loaves. Formalin-fixed tissue can 
still be used for qualitative and quantitative analysis 
of fluorescence imaging signal, in contrast to 
paraffin-embedded tissue, which is more suitable for 
qualitative data analysis. Cassetted, formalin-fixed 
tissues are ideal for identification of complex 
tumor-containing tissues since both the orientation 
and size are matched to the H&E-stained slide of that 
specific block after paraffin embedding. Quantitative 
analysis of formalin-fixed tissue can be performed in 
two ways. First, an absolute quantitative comparison 
of MFI from the raw data can be performed between 
tumor tissue and normal surrounding tissue, either 
per patient or per dose cohort, as demonstrated by an 
example in pancreatic cancer in Figure 4A. 
Alternatively, a semi-quantitative scoring method 
could be used to determine the percentage of 
fluorescent tissue, compared to the percentage of 
tumor tissue per tissue block (Figure 4B). The amount 
of tumor tissue can be assessed on the H&E slide from 
a particular block, while fluorescence can be 
measured either with a fluorescence scanner or a 
closed-field imaging device of a deparaffinized slide. 
Qualitative representation of ex vivo imaging 
preferably includes images of the ex vivo specimen, a 
bread loaf slice and the corresponding cassette to 
ensure correlation, as also shown in Figure 3. In this 
context, the bright field image, a black-and-white 
fluorescence image, and fluorescence overlay image 
should be shown of each specimen, and ideally also a 
fluorescence heat-map image. 
 
 
Figure 4. Quantitative analysis of ex vivo imaging. Quantitative analysis of formalin-fixed tissue can be performed in several ways. Two examples are shown here. (A) 
A quantitative comparison using the calculated MFI could be performed between tumor tissue and normal surrounding tissue, either per patient or per dose cohort. 
(B) A semi-quantitative scoring method could be used to determine the percentage of fluorescent tissue, compared to the percentage of tumor tissue per tissue 
block. 
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3. Target validation 
After paraffin-embedding of the tissue, the 
fluorescence signal will be attenuated. This influences 
the quantification properties of the signal. This, on the 
other hand, does not influence two other key aspects 
of data analysis in FGS trials. In the pathologic 
assessment one should focus on (1) confirmation of 
tumor targeting using histology, and (2) confirmation 
of molecular targeting of the biomarkers to the tumor 
cell. Lastly, correlation of fluorescence intensity with 
the density of the target molecule can be performed 
(Figure 1, panel III). Other key factors associated with 
delivery of the agent can also be assessed in this stage 
including vascular density, the presence or absence of 
lymphatic vessels, and the amount of cell 
proliferation. 
Confirmation of tumor cell targeting 
As discussed above, this step allows for direct 
correlation between tissue fluorescence and tumor 
status on H&E. In early phase trials, this step is critical 
to ensure the agent is indeed targeting the tumor. 
Confirmation of tumor status on the H&E slides 
should be performed in close collaboration with a 
trained pathologist, who is preferably blinded to the 
fluorescence imaging results. With the use of a 
fluorescence scanner, the location of fluorescence can 
be detected with a µm resolution. Because the tumor 
is often composed of stromal elements, it will be 
necessary to distinguish tumor/cancer cell targeting 
and targeting of other structures within the tumor 
mass. 
If the mapping process (as described above) is 
performed in a rigorous manner, the correlation 
generated at this step can be traced back to the images 
of the intact gross surgical specimen acquired during 
back-table imaging. It is even possible to apply this 
correlation back to the intraoperative findings; 
however, this is complicated by the necessary 
preservation of the specimen’s orientation at each step 
in addition to the influence of ambient light on 
intraoperative fluorescence. 
Confirmation of molecular targeting 
In the case of a targeted agent, the confirmation 
of precise tumor targeting should be a required step of 
the data analysis. Here, co-localization of the target of 
interest and fluorescence signal shows that the agent 
truly targets the biomarker, as compared to 
fluorescence signal seen in the tumor as a result of the 
EPR effect. A (semi-)quantitative analysis can be 
performed to analyze the fluorescence intensity 
relative to the receptor density of a specific tissue 
section (Figure 1). Co-localization can be performed 
using serial tissue sections, where one slide is used for 
immunohistochemistry (IHC) to confirm the target 
biomarker and one is used for fluorescence scanning. 
Additional IHC may be performed to gain a better 
understanding of the behavior of the factors 
influencing the tissue target; for example, for markers 
that influence delivery of the agent such as vascular 
density, the presence of lymphatic vessels, and the 
amount of cell turnover. Therefore, this staining will 
uniquely be performed during early phase trials when 
this information is relevant to advancing the agent 
and further characterizing its potential as a 
fluorescent biomarker. In later phase trials, one could 
choose to perform additional staining if the imaging 
results of a patient are out of the range of what is 
expected but would not necessarily be performed 
routinely. Fluorescence microscopy may be 
introduced into future analyses in FGS clinical trials in 
order to determine the position of the imaging agent 
in the tumor, e.g., membrane-bound, internalized, or 
in stroma. 
Summary and conclusion 
To ensure wide-spread use and FDA approval of 
FGS, the quality and standardization of reporting is 
paramount. Therefore, we present here 
recommendations for standardized reporting with the 
goal of establishing a set of minimum requirements 
for reporting FGS clinical trial results. In this 
approach, both qualitative and quantitative data play 
a major role. Three critical elements of early phase 
clinical trials can be identified and should be reported:  
1) Intra-operative data collection: FGS has the 
potential to play a unique role in the identification of 
tumor tissue, assessment of resection margins, and 
detection of tumor-positive lymph nodes, especially 
in locations that would suggest metastatic disease. In 
early phase trials, qualitative data should consist of 
multiple images obtained in each setting, which 
include a bright field image, a black-and-white 
fluorescence image, a pseudo-colored fluorescence 
overlay image, and/or a heat-map. Quantitative data 
should consist of numerical values reporting 
fluorescence, preferably both raw MFIs and a ratio 
such as TBR.  
2) Specimen mapping: This is critical to the 
validation of FGS to correlate fluorescence 
imaging-based results with the pathologic findings, 
preferably using fresh tissue. After imaging the fresh 
surgical specimen, the specimen should be formalin 
fixed. Formalin-fixed tissue can be used for qualitative 
and quantitative analysis of fluorescence signal, in 
contrast to paraffin-embedded tissue, which is more 
suitable for qualitative data analysis.  
3) Target validation: Co-localization of the target 
of interest and fluorescence signal needs to 
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demonstrate that the agent truly targets the 
biomarker. A semi-quantitative analysis can be 
performed to analyze the fluorescence intensity 
relative to the receptor density of a specific area.  
In summary, if these guidelines are widely 
accepted, trial results could be comparable and 
collated to expedite future FDA approval. 
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